Evidence map›Paper›PMID 42571385›Full record

ReviewJournal of bone oncology2026

Anti-resorptive agents in neuroendocrine bone metastases - A systematic review.

Marianne S Elston, Colin Chan Chui, Jade A U Tamatea, Ben Lawrence, Veronica Boyle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marianne S ElstonEndocrinology Unit, Te Whatu Ora Waikato, Waikato Hospital, New Zealand.
Colin Chan ChuiWaikato Clinical Campus, University of Auckland, Hamilton, New Zealand.
Jade A U TamateaEndocrinology Unit, Te Whatu Ora Waikato, Waikato Hospital, New Zealand.
Ben LawrenceDepartment of Medical Oncology, Te Whatu Ora Te Toka Tumai Auckland, New Zealand.
Veronica BoyleEndocrinology Unit, Te Whatu Ora Waikato, Waikato Hospital, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Bone metastases are common in patients with metastatic neuroendocrine neoplasms (NENs) and frequently result in skeletal complications. The current role of anti-resorptive agents for these patients is not known. Methods: A systematic review process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a PICOS framework searching the Embase, Medline, PubMed, Google Scholar, Cochrane library and Web of Science databases to identify studies reporting the use of anti-resorptive agents in patients with well-differentiated NENs who have bone metastases. Results: A total of 2424 articles were identified with 104 selected for full text review. After review, five retrospective studies were included in the review. Study design was heterogenous, and treatment details typically poorly described. A total of 348 patients were included in the review, of whom 206 received anti-resorptive treatment. One study ( Conclusion: Currently, there are insufficient data as to the role of anti-resorptive agents in patients with NENs and a prospective trial is needed.

Indexed as

BisphosphonatesBone metastasesDenosumabDiphosphonatesNeuroendocrine neoplasmNeuroendocrine tumour

Identifiers

PMID42571385
PMCPMC13452160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.